Ascletis Partners with Simcere for Ritonavir Supply in COVID-19 Drug Development
China-based Ascletis Pharma Inc. (HKG: 1672) has announced that its wholly-owned subsidiary Ascletis Pharmaceuticals Co.,...
HIV / AIDS care
Fosun Foundation Donates COVID-19 Therapy Azvudine to Rural China
The Fosun Foundation, Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196), and Henan...
Hainan Poly Pharm’s Generic Ganciclovir Approved in Denmark
China-based Hainan Poly Pharm Co., Ltd (SHE: 300630) has announced receiving marketing approval from the...
Jiangsu Aidea’s ACC007 Approved by NMPA for HIV-1 Treatment
China-based Jiangsu Aidea Pharmaceutical Co., Ltd (SHA: 688488) has announced that its Category 1 compound...
NMPA Approves Viatris’ Symfi Lo for HIV-1 Treatment in China
The National Medical Products Administration (NMPA) website indicates that US-based Viatris Inc.’s (NASDAQ: VTRS) Symfi...
Frontier Biotechnologies Partners with CASAPC for AIDS Prevention in China
China-based Frontier Biotechnologies Inc. (SHA: 688221) has announced a collaboration agreement with the Chinese Association...
GSK Partners with CASPC to Advance HIV Sustained Care Advocacy in China
The 5th China International Import Expo (CIIE) saw the unveiling of a partnership between GlaxoSmithKline...
Frontier Biotechnologies Secures Approval for HIV Therapy Alfusid
Nanjing-based Frontier Biotechnologies Inc. has announced that its supplementary market filing for Alfusid (albuvirtide), China’s...
China Approves GSK’s Juluca for HIV-1 Infection
The National Medical Products Administration (NMPA) has approved the market application for GlaxoSmithKline’s (GSK, NYSE:...
Brii Biosciences Reports Positive Phase I Results for HIV Treatments BRII-732 and BRII-778
China-based Brii Biosciences Limited (HKG: 2137) has published the latest results of two Phase I...
NMPA Approves IND Filing for Henan Genuine Biotech’s Long-Acting HIV Drug CL-197
China-based Henan Genuine Biotech Co., Ltd’s investigational new drug (IND) filing for its oral long-acting...
Beijing Launches HIV Precision Medicine Standardization Project
On September 17, an HIV precision medicine standardization project was initiated in Beijing. The project,...
Ascletis Completes Enrollment for HIV Functional Cure Study with PD-L1 Antibody ASC22
China-based Ascletis Pharma Inc. (HKG: 1672) announced that the clinical study of PD-L1 antibody ASC22...
Viatris Pharmaceuticals’ HIV/AIDS Drug Prioritized for CDE Review
The Center for Drug Evaluation (CDE) has indicated that Viatris Pharmaceuticals Co., Ltd’s efavirenz/lamivudine/tenofovir is...
Frontier Biotech Partners with Kindstar to Boost Anti-Infection Testing, Especially for HIV
China-based Frontier Biotechnologies Inc. (SHA: 688221) has entered into a partnership with compatriot firm Kindstar...
HeNan Genuine Biotech Files for IPO to Fund Azvudine Commercialization
China-based HeNan Genuine Biotech Co., Ltd has filed for an initial public offering (IPO) with...
Brii Biosciences Exercises Option for VIR-3434 in Greater China
China-based Brii Biosciences Limited (HKG: 2137) announced the exercise of its option to acquire exclusive...
Ascletis Pharma Doses First Patient in ASC22 HIV Study with Chidamide
China-based Ascletis Pharma Inc. (HKG: 1672) announced that the first patient has been dosed in...
Ascletis Pharma Doses First Patient in China’s Phase II Trial for HIV-1 Treatment with ASC22
China-based Ascletis Pharma Inc. (HKG: 1672) announced the dosing of the first patient in its...
Frontier Biotech’s Albuvirtide Shows Promising HIV Treatment Results in Phase III Trial
China-based Frontier Biotechnologies Inc. (SHA: 688221) has released Phase III trial data for albuvirtide, China’s...